Experience

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk advised the joint book-running managers in connection with the $97.75 million initial public offering of 9,775,000 units of Turmeric Acquisition Corp., which includes 1,275…

Davis Polk advised the representative of the initial purchasers of a Rule 144A/Regulation S offering by Acadia Healthcare Company, Inc. of $475 million aggregate principal amount of…

Davis Polk advised Smith & Nephew plc in connection with the establishment of a WKSI shelf and its debut SEC-registered shelf takedown of $1 billion aggregate principal amount of 2.032%…

Davis Polk advised the representatives of the several underwriters in connection with the $50 million initial public offering of common stock by Aziyo Biologics, Inc. The common stock…

Davis Polk advised the joint book-running managers in connection with a $216.2 million public offering of 5,750,000 shares of common stock by NanoString Technologies, Inc., which…

    Davis Polk advised the joint book-running managers and representatives to the underwriters in connection with the approximately $200 million follow-on public offering of…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…

Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …

Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…